Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies

Maxwell A. Stefani, Yooli K. Light*, Jennifer L. Schwedler**, Peter R. McIlroy, Colleen M. Courtney, Edwin A. Saada, Christine E. Thatcher, Ashlee M. Phillips, Feliza A. Bourguet, Catherine M. Mageenee, Summer A. McCloy, Nicole M. Collette, Oscar A. Negrete, Joseph S. Schoeniger, Dina R. Weilhammer, and Brooke Harmon

*Systems Biology Department, Sandia National Laboratories, Livermore, USA; **Biotechnology and Bioengineering Department, Sandia National Laboratories, Livermore, USA; †Biosciences and Biotechnology Division, Lawrence Livermore National Laboratories, Livermore, USA

ABSTRACT
The respiratory virus responsible for coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life worldwide, claiming the lives of over 3.9 million people globally at the time of this publication. Neutralizing humanized nanobody (VH,H)-based antibodies (VH,H-huFc) represent a promising therapeutic intervention strategy to address the current SARS-CoV-2 pandemic and provide a powerful toolkit to address future virus outbreaks. Using a synthetic, high-diversity VH,bacteriophage library, several potent neutralizing VH,huFc antibodies were identified and evaluated for their capacity to tightly bind to the SARS-CoV-2 receptor-binding domain, to prevent binding of SARS-CoV-2 spike (S) to the cellular receptor angiotensin-converting enzyme 2, and to neutralize viral infection. Preliminary preclinical evaluation of multiple VH,huFc antibody candidates demonstrate that they are prophylactically and therapeutically effective in vivo against wildtype SARS-CoV-2. The identified and characterized VH,huFc antibodies described herein represent viable candidates for further preclinical evaluation and another tool to add to our therapeutic arsenal to address the COVID-19 pandemic.

Introduction

The novel respiratory virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 146 million and killed over 3 million people worldwide, causing the worst global health crisis since the 1918–1919 influenza pandemic. In addition to the lives lost to COVID-19, this virus has wreaked havoc on the global economy and highlighted the threat that emerging diseases pose to global security. It is important not only to work to develop effective vaccines for pre-exposure prophylaxis, but to create new treatments to prevent and mitigate severe disease.

Viral neutralizing antibodies are an effective therapeutic intervention for COVID-19, as the current pandemic response has shown. High titer convalescent plasma has emergency use authorization by the U.S. Food and Drug Administration (FDA) for the treatment of hospitalized patients early in the disease course and/or with impaired humoral immunity; however, batch-to-batch variability results in various levels of success, limiting its reliability as a treatment. Monoclonal antibody therapies, like convalescent plasma, block cell entry, the first step of virus infection, but consist only of highly neutralizing antibodies with high target specificity, and more favorable pharmacokinetics. Recently, promising clinical trial data demonstrated that a single intravenous infusion of monoclonal antibody (mAb) cocktail significantly reduced COVID-19 related hospitalization and death in comparison to placebo. These results and other clinical trial findings supported FDA’s emergency use authorization of three mAb cocktails for people 12 y and older who test positive for SARS-CoV-2 and are at high risk for progressing to severe COVID-19. Methods for improved development and characterization of novel neutralizing antibodies can be part of a critical toolset to combat the COVID-19 pandemic and future epidemics, by providing lower cost, easier manufacturability, and diverse functionality, including response to emerging variants.

Nanobodies (VH,H) are the variable region of single-domain heavy chain only antibodies (sdAbs), which lack the light chain and the CH1 domain, are derived from camels, and are smaller (~75 kDa) than human or murine immunoglobulin G (IgG) antibodies (150kDa). VH,H antibodies are highly soluble, stable, extremely versatile, and have unique structural attributes in their complementarity-determining region 3 (CDR3) loop that can facilitate binding to antigen sites inaccessible to traditional IgG antibodies. Neutralization of SARS-CoV-2 is achieved by targeting antibodies to the spike (S) receptor-binding domain (RBD), which engages the angiotensin-converting enzyme (ACE2) receptor to facilitate cell entry. The S protein is heavily glycosylated, limiting viable epitope availability with potential for therapeutic efficacy. Compact VH,H-based antibodies may have access to alternate epitopes on the SARS-CoV-2 S protein that are sterically inaccessible to traditional antibodies.

Herein, we describe a rapid discovery process for SARS-CoV-2 VH,H-based antibody therapeutics, from molecular...
discovery of high-affinity variable regions to demonstration of therapeutic efficacy of fully humanized V_{H}H-based antibodies in mice infected with SARS-CoV-2. We describe the construction of a high-diversity synthetic humanized V_{H}H phage library (~3.2 x 10^{10}) that was used to identify several V_{H}H antibodies that are high-affinity binders to SARS-CoV-2 S protein and RBD. The top V_{H}H candidates were produced as human sdAbs with the crystallizable fragment (Fc) domain of a human IgG1 (V_{H}H-huFc) and were evaluated for their ability to block the interaction between purified SARS-CoV-2 S and the ACE2 receptor. Effective V_{H}H-huFc antibodies were then screened for their ability to block infection of Vero cells with SARS-CoV-2 pseudotyped vesicular stomatitis virus (VSV-SARS-CoV-2-GFP), followed by verification of neutralization of wildtype (wt) SARS-CoV-2 (USA-WA 1/2020). The epitope targets were mapped by sequencing neutralization escape mutants generated in the presence of each V_{H}H-huFc. The binding affinity of the V_{H}H-huFc antibodies to RBD with mutations generated in this study, including the L452R mutation found in the Epsilon (B.1.427 and B.1.429), Kappa (B.1.617.1) and Delta (B.1.617.2) variants, or from the Alpha (B.1.1.7) and Beta (B.1.351) variants, was assessed with kinetic studies using biolayer interferometry (BLI). We also demonstrate that two of these V_{H}H-huFc antibodies show efficacy in vivo both prophylactically and therapeutically against challenge with fully virulent wt SARS-CoV-2.

Results

Library construction

The V_{H}H library incorporated both the diversity and prevalence of amino acids at key positions in each of the CDR1 and CDR2 derived from a single domain antibody (sdAb) database (Figure 1a).14 This database contains sequences of validated sdAbs or nanobodies from both synthetic and natural sources from both naïve and immune repertoires. This database has been curated using sequences derived from existing databases (Protein Data Bank and NCBI) and publications. We examined the amino acid diversity and prevalence at each position in CDR 1 and 2 from 670 of these nanobodies and incorporated this into our custom library synthesis. FCDR3, full amino acid

Figure 1. Development of high-diversity V_{H}H library and screening campaign for SARS-CoV-2 neutralizing V_{H}Hs. A) Library design using deposited sequences of functional V_{H}Hs from various sources. Data was mined to determine optimal CDR length and amino acid prevalence at each amino acid position within each respective CDR. B) Schematic for the biopanning approach used to identify neutralizing V_{H}Hs directed to the SARS-CoV-2 RBD. C) Polyclonal ELISA against multiple antigens show enrichment of a positive SARS-CoV-2 binding population of displayed V_{H}H with each sequential round of panning. Data is from experimental conditions performed in triplicate; the error is the standard deviation from the mean (**, P < .001; *, P < .01; *, P < .05). The data represent one of three experiments with similar results.
diversity was included, and three different lengths were used: 9-, 12-, and 15-amino acids. The length for each CDR 1 and 2 was based on the predominant lengths of these loops observed in the functional sdAb database. (Figure S1). Cysteines and methionines were omitted from all CDRs. The sequence used for the framework to house the custom made CDRs, hs2dAb, was derived from Moutel et al. In this framework, multiple residues are changed such that the framework more closely mirrors germline human VH3 immunoglobulin. The library was synthetically produced and the observed prevalence of amino acids at each of the CDR loops paralleled the desired prevalence as determined by next-generation sequencing (NGS; data not shown).

To obtain sufficient diversity coverage for the library (i.e., transformants), 150 electroporations were performed yielding approximately $3.38 \times 10^{10}$ transformants. To determine the level of success for the ligation of the library into the vector backbone, colony PCR was performed. Of the 408 colonies selected, 395 contained the correct size amplified DNA fragment (95.9%). This value was used to adjust the calculated value for library diversity to $3.24 \times 10^{10}$. Finally, library diversity, quality, and the distribution of CDR3 lengths were assessed by NGS from a total of 39,870,360 reads (Tables S1 and S2). The 9-amino acid CDR3 was the most prevalent at 40%, followed by 12-amino acid CDR3 at 34%, and lastly the 15-amino acid CDR3 at 25% of the observed diversity. Overall, there was good coverage of all represented CDR3s. Approximately 1% of sequences contained a stop codon and 99% of reads were unique sequences (38,592,027 reads). Roughly 1% of reads were duplicates, and 0.01% (1,095 sequences) were present in triplicate. With these corrections the adjusted diversity for this nanobody library is $3.18 \times 10^{10}$.

**Panning against SARS-CoV-2 S and RBD**

Four rounds of biopanning were used to identify clones that bind to the SARS-CoV-2 S protein RBD. For the first three rounds, full-length soluble purified SARS-CoV-2 S protein confirmed as a trimer was used, ensuring that conformational integrity of the RBD was maintained for initial selection. A 15-minute heat denaturing step at 70°C was used to remove unstable sequences and a final round of biopanning against SARS-CoV-2 RBD was conducted to identify therapeutically relevant V_{H}H antibodies (Figure 1b). Enrichment of phage against SARS-CoV-2 S was observed over the initial three rounds of biopanning (Figure 1c and Table S3) and there was a significant loss in phage recovered when the antigen was shifted to RBD (0.0005% compared to 0.004%).

Polyclonal ELISA showed that enrichment for SARS-CoV-2 S binders occurred over each round of biopanning. Interestingly, there was relatively little SARS-CoV-2 RBD binding until panning was conducted against RBD specifically, indicating preferred epitopes are outside the RBD (Figure 1c). Additionally, neutralization of SARS-CoV-2 pseudotyped vesicular stomatitis virus encoding enhanced green fluorescent protein (eGFP) (VSV-SARS2-GFP) was only observed after RBD biopanning (R4), showing enrichment for RBD binders is required to remove clones binding to epitopes outside the RBD and to identify virus neutralizing clones (Figure 1d). Monoclonal characterization was performed using ELISA; 222 of the 384 clones were designated as hits. Clones that had OD_{450} ≥ 2.5 in the phage coat monoclonal ELISA against both SARS-CoV-2 S and RBD and that did not bind bovine serum albumin (BSA) were designated as hits (Figure S2). Of those designated as hits, 54 sequences were identified as unique.

**Evaluation of V_{H}H-huFc candidates**

Humanized V_{H}H-huFc antibodies were produced as a fusion to the hinge region and the Fc domain of human IgG1, which combines the advantages of the V_{H}H with the improved half-life and effector functions of human IgG1 while reducing the overall size by half that of a conventional antibody, improving circulation and increasing their ability to penetrate target tissues in the body. All 54 unique V_{H}H sequences were commercially produced in a V_{H}H-huFc format by GenScript for further characterization and triage (Figure 2a). Of the 54 V_{H} H-huFc antibodies, 49 showed positive binding to both SARS-CoV-2 S and RBD, with little to no binding to BSA by ELISA (Figure S3). Those that showed positive binding by ELISA were then tested for their ability to compete with ACE2-huFc for binding to SARS-CoV-2 S by a competition ELISA (Table S4). Finally, 46 candidates were evaluated for their ability to neutralize VSV-SARS-CoV-2-GFP infection in vitro, with 34 V_{H}H-huFc antibodies demonstrating full or partial neutralization of infection (Table S4).

For reconfirmation of binding and neutralization, 16 V_{H} H-huFc antibodies were selected based on low 50% effective inhibitory concentration (EC_{50}) values and were produced and purified in-house (Figure S4). None of these candidates inhibited infection with pseudotyped, single-cycle VSV particles displaying the SARS-1 S protein (VSV-SARS-1-GFP), indicating specificity for SARS-CoV-2 S protein (Figure S4E). Three of the 16 V_{H}H-huFc antibodies, SP1B4, SP1D9, and SP3H4, were identified as showing the greatest potency in viral neutralization with EC_{50}s of 0.33, 0.45, and 0.14 nM, respectively, against VSV-SARS-CoV-2-GFP and EC_{50}s of 3.14, 1.12, and 0.70 nM, respectively, against wtSARS-CoV-2 by a plaque neutralization assay (Figure 2c, Figure 2f). The neutralization values were obtained with three independent virus-based assays (Table S5), suggesting that SP1B4, SP1D9, and SP3H4 are potent neutralizers of SARS-CoV-2, and this observed potency correlates with their strong competition with ACE2 for binding to SARS-CoV-2 S protein (Figure 2d). The thermal stability of V_{H}H-huFc antibodies was evaluated by differential scanning fluorimetry (DSF). Melting temperatures for SP1B4, SP1D9, and SP3H4, 60.4°C, 64.0°C, and 61.0°C, respectively, are comparable to previously reported SARS-CoV-2 neutralizing V_{H}H-huFc antibodies (Figure 2j, S5).

Dissociation constants were determined for the V_{H}H-huFc antibodies using BLI, revealing high affinity for the SARS-CoV-2 RBD of 39.5 nM and 8.9 nM for SP1B4 and SP1D9, respectively (Figure 2g,h). SP3H4 exhibited biphasic association and dissociation kinetics that could not be reconciled with a 1:1 global fit analysis, and it was therefore not given kinetic parameters (Figure 2i).
Figure 2. Evaluation of V$_{H}$-H-huFc candidates. A) Triage flowchart for selection of top candidates, from clonal phage ELISA to selection of 16 candidates for reconfirmation. B) Reconfirmation ELISA of top three candidates binding to SARS-CoV-2 S and RBD. C) SARS-CoV-2 RBD. D) Top candidate V$_{H}$-H-huFcs compete with ACE2-huFc for binding to SARS-CoV-2 S by competition ELISA and E) neutralize VSV-SARS-CoV-2 GFP infection of Vero cells. The data for a–e are from experimental conditions performed in triplicate, the error is the standard deviation from the mean. F) All three V$_{H}$-H-huFcs also neutralize wt SARS-CoV-2 in a plaque reduction neutralization assay. The data from this is the mean of the plaque assay performed in duplicate, the error is the standard deviation from the mean. BLI sensorgrams show binding to SARS-CoV-2 RBD by SP1B4 (g), SP1D9 (h), and SP3H4 (i). At least five concentrations were used for global fit analysis. J Table summarizing kinetic properties, neutralizing efficacy, and thermal stability properties for SP1B4, SP1D9, and SP3H4. Melting temperatures from DSF were determined from two independent experiments each performed in triplicate.

Epitope mapping by escape mutant formation and BLI

Epitopes were mapped by sequencing VSV-SARS-CoV-2-GFP virus containing escape mutants generated in the presence of SP1B4, SP1D9, or SP3H4, followed by confirmation with BLI binding studies of escape mutant SARS-CoV-2 RBDs (Figure 3). Within 48–60 hours of the first passage, viral escape was apparent from all V$_{H}$-H-huFc antibodies at the highest concentration tested, with all cells expressing GFP. The viral supernatant used for the second passage was completely resistant to neutralization from a 15-fold excess of the corresponding V$_{H}$-H-huFc (Figure 3c). Escape mutations were characterized by RNAseq for each of the VSV-SARS-CoV-2-GFP supernatants (Figure 3d). Interestingly, for SP1B4 and SP1D9, E484K (the mutation found in the Beta variant) seems to be selected against in the second passage and Q493R and S494P seem to stabilize as the predominant mutations observed (Figure 3d). This may indicate these two V$_{H}$-H-huFc antibodies have similar binding modes. For SP3H4, the predominant escape mutation observed was L452R, and no shared mutations with SP1B4 and SP1D9 were detected.

SARS-CoV-2 RBD variants with single mutations were produced and their affinity for human ACE2 and the three V$_{H}$ H-huFc antibodies was determined by BLI (Figure S6-S9 and Table S6). In all cases, individual mutations were shown to have little to no impact on ACE2 binding, suggesting minimal impact on viral infection. Mutations in the RBD significantly affected
V1-H-huFc binding. Interestingly, SP3H4 maintained the ability to bind to L452R, despite this being the predominant mutation observed in the escape mutant VSV-SARS-CoV-2-GFP virus generated. Additionally, BLI results show 1:1 binding kinetics for SP3H4 binding to the L452R mutant RBD. The biphasic kinetics observed with SP3H4 and wt RBD combined with the 1:1 binding kinetics of SP3H4 for RBD with the L452R mutation may indicate that SP3H4 has multiple binding sites. SP1D9 maintained the ability to bind many of the point mutations generated, though binding was abrogated by Q493R and S494P (Figure 3d) as expected based on the escape mutant analysis. All mutations generated in RBD abrogated binding by SP1B4.

Next, SARS-CoV-2 RBDs from the Alpha and Beta variants were characterized for affinity to the human ACE2 receptor and top V1-H-huFc antibodies identified in this study (Figure S6-S9 and Table S6). The Alpha variant RBD showed an ~5-fold increased affinity to the ACE2 receptor (K_D = 2.5 nM vs 13.3 nM for WT). While SP1B4 (K_D = 97.7 nM) and SP1D9 (K_D = 49.7 nM) maintained binding affinity for the Alpha RBD, there was a 2.5 -fold and 5.5 -fold decrease in affinity in comparison to the wt or Wuhan RBD (K_D = 39.5 nM, and 8.9 nM, respectively, (Figure S7-S8)) and a visible difference in binding to this RBD for SP3H4 (Figure S9). For the SARS-CoV-2 RBD from the Beta variant, the K_D for ACE2 was similar to the K_D for the Wuhan strain, but there was no detectable binding for SP1B4, SP1D9, or SP3H4 (Figure S7-S9).

Preclinical evaluation of V1-H-huFc antibodies:

Top performing V1-H-huFc antibodies SP1B4, SP1D9 and SP3H4 were assessed for in vivo prophylactic (~24 hours) and therapeutic (+24 hours) efficacy against fully virulent wt SARS-CoV-2 using the recently described K18-hACE2 transgenic mouse model of SARS-CoV-2 infection. Two of the three V1-H-huFc antibodies tested, SP1D9 and SP3H4, provided very
significant protection \((p < .0001)\) over the isotype control in prophylactically dosed mice. Although SP1B4 was a potent neutralizer in vitro, it did not demonstrate efficacy against challenge with SARS-CoV-2 in vivo \(\text{(Figure 4a, Figure 4b)}\) and was not pursued in further in vivo studies. The SP1D9 group showed 94% survival \((n = 16)\), and the SP3H4 group showed 87.5% survival \((n = 16)\) at 10 dpi post infection \((\text{dpi})\), indicating effective neutralizing activity in vivo \(\text{(Figure 4a)}\). While 81.3% \((n = 16)\) of control-treated mice lost more than 20% of their starting weight by 6 dpi, requiring euthanasia, those pretreated with SP1D9 lost an average of only 3.9% \((\pm 4.8\%)\) of their starting weight \(\text{(Figure 4b and Figure S10)}\). Similarly, the SP3H4-dosed group exhibited a 5.4% average \((\pm 9.3\%)\) weight loss. Animals dosed prophylactically with the poorest performing \(V_\text{H}H-huFc\), SP1B4, lost an average of 17.7% \((\pm 8.3\%)\) of their starting weight, with 50% of animals succumbing to infection by 6 dpi \(\text{(Figure 4b \\& Figure S10)}\).

Since SARS-CoV-2 viral titers peak as early as 48 hours post-infection \((\text{hpi})\) in vivo, allowing the virus to establish infection for 24 hours prior to therapeutic administration should demonstrate the versatility of these \(V_\text{H}H-huFc\) antibodies in disease treatment. To evaluate the efficacy of SP1D9 and SP3H4 \(V_\text{H}H-huFc\) antibodies post-exposure, mice were infected intranasally with \(2.5 \times 10^4\) plaque forming units \((\text{PFU})\) SARS-CoV-2, then administered 10 mg/kg of \(V_\text{H}H-huFc\) antibodies 24 hpi. Impressively, both SP1D9 and SP3H4 demonstrated significant therapeutic protection \((p = .0033, p = .0013, \text{respectively})\) over that of the isotype control. The SP1D9 group showed 58% survival \((n = 8)\), and the SP3H4 group showed 75% survival \((n = 8)\) at 10 dpi \(\text{(Figure 4c)}\). Of note, several surviving individuals in each of the post-exposure \(V_\text{H}H-huFc\)-treated groups exhibited 10–15% weight loss up to 5 dpi, but then rebounded from 6 to 10 dpi, gaining back 90–95% of their starting weight \(\text{(Figure 4d and Figure S10)}\). Taken together, these data demonstrate protection from lethal infection after a single 10 mg/kg dose, and further suggest that neutralization of SARS-CoV-2 by \(V_\text{H}H-huFc\) antibodies in vivo can promote recovery from an ongoing infection.

**Discussion**

The COVID-19 pandemic caused by SARS-CoV-2 has resulted in 184 million cases and over 3.9 million deaths and an estimated global economic cost of over 10.3 trillion dollars in forgone output for 2020 and 2021.\(^{19}\) As variants of SARS-CoV-2 emerge, it is essential to possess a diverse set of prophylactic and therapeutic tools, in order to maintain the progress made toward ending this pandemic. While vaccines have been a great success, therapeutic biologics are emerging as a critical tool in preventing progression to severe disease in those who become infected.\(^{20}\)

Several therapeutic antibody candidates with efficacy against SARS-CoV-2 have been recently identified, including three with emergency use authorization, but there are a number of caveats associated with conventional antibodies as therapeutics, such as reliance on immunized or patient sera, expensive and labor-intensive production, and the large doses required to achieve clinical efficacy.\(^{21–24}\) High stability, solubility, and the ability to be multimerized are a few of the many

---

**Figure 4.** Top \(V_\text{H}H-huFc\) candidates provide protection from lethal SARS-CoV-2 infection in vivo. Kaplan–Meier curve illustrating percentage survival of K18-hACE2 mice infected intranasally with \(2.5 \times 10^4\) PFU SARS-CoV-2 and dosed with 10 mg/kg \(V_\text{H}H-huFc\) via intraperitoneal injection prophylactically \((a)\) at 24 hours prior to infection or therapeutically \((c)\) at 24 hpi. A log rank test was performed with Bonferroni multiple comparison correction applied. \(B\) Percentage weight loss for mice in \((a)\). \(D\) Percentage weight loss for mice in \((c)\). For \((b)\) and \((d)\), statistical analyses were performed at time points when all mice were alive to avoid survivor bias. Data displayed are the mean ± standard error of the mean. \(A\ & B\) Isotype control \(n = 16\), SP1B4 \(\text{(<—24 hpi)}\) \(n = 8\), SP1D9 \(\text{(<—24 hpi)}\) \(n = 16\), SP3H4 \(\text{(<—24 hpi)}\) \(n = 16\). \(C\ & D\) Isotype control \(n = 8\), SP1D9 \(\text{(<—24 hpi)}\) \(n = 8\), SP3H4 \(\text{(<—24 hpi)}\) \(n = 8\). Data represent two experiments \((**** p < .0001; ** p < .01; ns = not significant).\)
reasons why \( V_{1H} \)-based antibody therapeutics (\( V_{1H}\-\text{Fc} \)) represent a highly promising method for treatment.\(^{12} \) One \( V_{1H} \)-based therapeutic is approved by the FDA for treatment of a rare blood clotting disorder and many more are in late stage clinical trials.\(^{12,25} \) The small size of \( V_{1H}\-\text{huFc} \) antibodies and the wider distribution of CDR3 loop lengths compared to human IgGs expands the type of epitope that can be effectively targeted.\(^{13,14} \) Finally, preliminary evidence suggests that \( V_{1H}\-\text{Fc} \) antibodies are transported more efficiently into the blood and lung parenchyma following intraperitoneal administration compared to conventional IgG1 antibodies.\(^{26,27} \) Several groups have recently used \textit{in vitro} screening techniques to identify \( V_{1H} \) domains with high affinity for the SARS-CoV-2 S protein and neutralization of SARS-CoV-2 with EC\textsubscript{50}s ranging from 0.02 nM to 2 \( \mu \)M in pseudotyped virus and in \( wt \) SARS-CoV-2 virus assays.\(^{25,26,28–34} \) However, in addition to neutralization, there are several antibody and immune functions that contribute to prophylactic and therapeutic effectiveness \textit{in vivo}, and only one of these studies characterized the \textit{in vivo} efficacy of a single \( V_{1H}\-\text{Fc} \) construct (\( V_{1H}\-\text{Fc} \) ab8) at reducing lung viral titers at 2 or 5 d post infection.\(^{26} \) Importantly, the mouse-adapted SARS-CoV-2 and the golden hamster SARS-CoV-2 infection models used in this study are not lethal, rather, they inform efficacy for more mild disease cases.\(^{18,26,35,36} \) In this regard, the K18-hACE2 SARS-CoV-2 infection model is particularly valuable for testing the protective and therapeutic properties of novel antibodies in the context of severe infection and disease.\(^{37,38} \)

In this study, we identified and characterized several prospective therapeutic neutralizing \( V_{1H}\-\text{huFc} \) antibodies both \textit{in vitro} and \textit{in vivo} from a high diversity synthetic library. Three candidate \( V_{1H}\-\text{huFc} \) antibodies are highlighted in this study because of their potent sub-nanomolar EC\textsubscript{50}s in preventing viral infection. For the SP1B4, SP1D9, and SP3H4 \( V_{1H}\-\text{huFc} \) constructs, affinity maturation was not required to achieve potent neutralization against SARS-CoV-2 pseudovirus (EC\textsubscript{50}s of 0.33, 0.45, and 0.14 nM, respectively) or \( wt \) SARS-CoV-2 virus (EC\textsubscript{50}s of 3.14, 1.12 and 0.70 nM, respectively).

Two of the \( V_{1H}\-\text{huFc} \) antibodies provided protection of K18-hACE2 transgenic mice when administered 24 hours before infection with \( wt \) SARS-CoV-2. A single dose of SP1D9 or SP3H4 exhibited significant therapeutic value when administered a full 24 hpi, which is closer to the peak of infection than was used to evaluate therapeutic efficacy of \( V_{1H}\-\text{Fc} \) ab8 (6 hpi).\(^{26,37} \) In this study, the onset of weight loss at 2–4 dpi, indicative of effective disease progression, and subsequent improvement after treatment establishes the potential for efficacy in the presence of an established \( wt \) SARS-CoV-2 infection (\textit{Figure 4d and Figure S10}). Although SP1B4 was a potent neutralizer \textit{in vitro}, it failed to protect mice from infection with \( wt \) SARS-CoV-2, highlighting the importance of animal validation studies to triage top candidates for clinical evaluation.

Selection for escape mutants by individual \( V_{1H}\-\text{huFc} \) antibodies demonstrate the high propensity for SARS-CoV-2 to escape neutralization \textit{in vitro}. Several studies, including this one, have generated mutations \textit{in vitro} that exist in circulating SARS-CoV-2 variants and revealed that these mutations partially or completely block binding of top anti-SARS-CoV-2 therapeutic antibodies.\(^{39} \) The potential for continued mutation acquisition and escape in SARS-CoV-2 highlights the critical importance of having multiple options for antibody cocktails.\(^{29} \) Furthermore, sequencing analysis of the latest strains’ mutation status would allow patient stratification to identify which therapeutic regimen will be most effective in combating the latest emerging variant.\(^{29} \)

In this study, viral escape was readily apparent in the presence of our top candidates, with several mutations in the RBD. Interestingly, many of the initial mutations were selected against in the second passage (\textit{Figure 3}), and none of these individual mutations in the RBD significantly affected binding to ACE2 (\textit{Figure 3d and Figure S6}). This suggests that these positions of the S gene are highly susceptible to single-nucleotide polymorphisms and should be considered when identifying future preclinical antibody candidates because they may be present in future variant strains. Escape mutations observed for our two most promising candidates are all found in proximity to each other, likely indicating overlapping epitopes, though they may engage this epitope with different geometries (\textit{Figure 3}). SP3H4 did not share any of the mutations observed for SP1B4 or SP1D9, indicating that SP3H4 may engage the RBD region differently.

All three \( V_{1H}\-\text{huFc} \) antibodies neutralize viral infection by targeting the RBD of the \( wt \) SARS-CoV-2 S protein and compete directly with ACE2 binding to trimeric SARS-CoV-2 S, which indicates they are class I nanobodies.\(^{35} \) Although the \( V_{1H}\-\text{huFc} \) antibodies described in this study bind to a single epitope, other groups have recently identified \( V_{1H} \) antibodies that target a distinct epitope and could be used in combination with the \( V_{1H} \) antibodies identified in this study to develop highly potent therapeutic cocktails that prevent the emergence of escape mutants.\(^{29,31,34} \)

We also evaluated our \( V_{1H}\-\text{huFc} \) antibodies’ ability to engage RBDs with mutations found in clinically relevant SARS-CoV-2 variants, including the L452R mutation found in the Epsilon (B.1.427/B.1.429), Kappa (B.1.617.1) and Delta (B.1.617.2) variants, and the mutations found in the Alpha (B.1.1.7) and Beta (B.1.351) variants, which pose a significant hurdle to therapeutic efficacy and vaccine-derived immunity. Interestingly, we observed a ~5-fold increase in affinity of the Alpha variant RBD for the ACE2 receptor, which may account for the increased infectivity observed with this strain of SARS-CoV-2. While none of our most promising candidates bind to the Beta variant, SP1B4, SP1D9, and SP3H4 still bind the Alpha RBD variant, albeit with reduced affinity in comparison to \( wt \) SARS-CoV-2 RBD (\textit{Figure S7–S9}). The E484K mutation, observed in the Beta variant and now a new Iota (B.1.526) variant, confers total abrogation of \( V_{1H}\-\text{huFc} \) binding. The L452R mutation, found in circulating Epsilon, Kappa, and Delta variant strains, was selected for with SP3H4.\(^{40–42} \)

Interestingly, SP3H4 retains affinity for SARS-CoV-2 RBD with the L452R mutations. Furthermore, the kinetics appear to shift from biphasic to 1:1 with the L452R mutation, which may indicate that SP3H4 has two non-overlapping binding sites.

While many of the mutations in clinically relevant SARS-CoV-2 variants emerged in this study, several mutations that arose in this study have yet to be highlighted. Using these \( V_{1H} \) H-huFc antibodies to rapidly generate escape mutants could help to preemptively identify and develop countermeasures for
future variants before they arise and circulate in the population.

In this work, we reported the design of a large synthetic \( V_{H} \) H library (3.18 \( \times 10^{10} \)) and described the library’s utility in identifying over 50 \( V_{H} \) H candidates that bind to \( wT \) SARS-CoV-2. We triaged top candidates based on neutralization efficiency \( in vitro \), and evaluated efficacy \( in vivo \) using a mouse model of severe SARS-CoV-2 disease. To our knowledge, this is the first study to examine survival up to 10 dpi with a single dose of \( V_{H} \) H-Fc given 24 hpi in the context of a lethal SARS-CoV-2 infection. While \( in vitro \) neutralization assays and short-range \( in vivo \) titer reduction studies are informative, they do not always recapitulate likelihood of survival. There are several reasons why \( in vitro \) potency may not correlate with \( in vivo \) protection, including an antibody’s pharmacokinetic properties and/or a broad range of immunomodulatory functions required for viral clearance.\(^{38,43–45} \) Studies are currently underway to evaluate the efficacy of \( V_{H} \) H-huFc combinations administered at later time points post-infection and to investigate the role of Fc effector function in protection against SARS-CoV-2. The demonstrated ability of this virus to generate escape mutants emphasizes the need for multiple therapeutic options, with demonstrated \( in vivo \) activity in a post-infection context, to rapidly react to the emergence of resistant variants as expanded vaccine and antibody therapy use creates selection pressures on the viral population.

**Materials and methods**

**DNA manipulation and production of proteins**

pSF-CMV-SARS-CoV-2-S was constructed as follows. DNA fragments encoding amino acids 1–1208 of the SARS-CoV-2 S gene (GenBank:MN908947.3) were amplified as several independent fragments to introduce several mutations described in Wrapp et al.\(^{46} \) from a vector containing the full-length codon-optimized S gene. Additionally, a double-stranded DNA fragment encoding a C-terminal T4 fibrinogen trimerization domain, TEV cleavage site, Twin-Step-Tag, and octahistidine was commercially obtained. pSF-SARS-CoV-2-RBD was produced by commercial production of double-stranded DNA encoding a N-terminal Kozak, a signal peptide (MDWTWRFLFVVAATGVQS), 319–577 of the SARS-CoV-2 S gene (GenBank:MN908947.3), a TEV site, and a C-terminal, decahistidine tag. Mutant SARS-CoV-2 RBDs were produced by site-directed mutagenesis. All fragments were synthesized commercially (IDT) and terminal fragments had overlapping sequence with the downstream digested vector. All DNA fragments and pSF-CMV vector restriction digested with EcoRI and BamHI were assembled using NEBuilder HiFi DNA master (NEB, E26215).

Constructs for expression of ACE2-Fc (human Fc domain) fusion proteins were produced as follows. pAce2-huFc was produced by subcloning the ectodomain of human ACE2 (Sino Biological) into pCR-Fc using the NotI and BamHI restriction sites. To produce Ace2-rbFc (rabbit Fc domain), a gBlock (IDT) of this same region of Ace2 was subcloned into pFUSE RlgG-Fc2 (Invivogen, pfuse-rfc2).

Soluble SARS-CoV-2 S and RBD were both produced by transient expression in Expi293F suspension cells (Thermo, A14527). Cells were transfected with 1 \( \mu g/mL \) plasmid at a density of 3.0 \( \times 10^{6} \) cells/mL using Exipfectamine (Thermo, A14635). Cells were supplemented as instructed by the manufacturer and grown at 37°C with 8% CO\(_2\). Cell supernatant was harvested on day 4 by centrifugation at 4,000 x g for 30 min at 4°C. Clarified supernatant was passed through a 0.22 \( \mu m \) filter and then applied to a 5 mL HisTrap Excel column (Cytiva, 17,371,206) pre-equilibrated with 10 mM Tris (pH 8.0), 300 mM NaCl for SARS-CoV-2 S and 20 mM phosphate (pH 7.4), 300 mM NaCl for SARS-CoV-2 RBD. The column was washed with 10 column volumes equilibration buffer followed by 5 column volumes equilibration buffer with 20 mM imidazole. The S and RBD proteins were eluted with a step gradient to 500 mM imidazole. Fractions containing SARS-CoV-2 S protein were pooled and dialyzed in 20 mM HEPES (pH 8.0), 200 mM NaCl, prior to concentration. Protein was then concentrated and filtered prior to application to an Enrich 650 SEC column (Biorad, 7,801,650) equilibrated with dialysis buffer for SARS-CoV-2 S and phosphate-buffered saline) PBS for SARS-CoV-2 RBD. Purified SARS-CoV-2 proteins were stored at −80°C.

ACE2-huFc, ACE2-rbFc, and \( V_{H} \) H-huFc antibodies were produced by transient expression in CHO-S cells using the ExpiCHO expression system (Thermo, A29133). In brief, cells were transfected at a density of 6 \( \times 10^{6} \) cells/mL and grown for 18 hours at 37°C with 8% CO\(_2\). Cells were then supplemented as per the manufacturer’s guidelines and transferred to 32°C with 5% CO\(_2\). Cell supernatant containing soluble protein was harvested on day 10 by centrifugation at 4,000 x g for 30 min at 4°C. Clarified supernatant was passed through a 0.22 \( \mu m \) filter and the applied to a 1 mL HighTrap MabSelect PrismA column (Cytiva, 17,549,851). The column was washed with 20 mM sodium phosphate (pH 7.4), 150 mM NaCl. ACE2-Fc fusion proteins were eluted with 100 mM sodium citrate (pH 3.0) and immediately neutralized with 1 M Tris (pH 9.0). Protein was then concentrated and filtered before application to an Enrich 650 SEC column equilibrated with 10 mM sodium phosphate (pH 7.2), 140 mM NaCl. Purified ACE2-huFc, ACE2-rbFc, and \( V_{H} \) H-huFc were stored at −80°C. \( V_{H} \) H-huFc antibodies identified from screening were commercially obtained from GenScript.

**V\(_{H}\)H phage library construction and production**

Synthetic \( V_{H} \)H library was designed as follows. A high diversity library was designed by incorporating the natural prevalence of amino acids at positions in CDR1 and CDR2 based off 670 functional \( V_{H} \)H antibodies deposited on sdAb-DB (www.sdab-db.ca).\(^{14} \) Amino acids cysteine and methionine were omitted from all CDR loops and full diversity was used for CDR3. Asparagine was also omitted from CDR1 and CDR2. The library was also designed such that there would be 3 different lengths of CDR3 (9-, 12-, and 15-amino acids). Linear double-stranded DNA fragments incorporating the specifications mentioned above, as well as terminal flanking BglI restriction sites, were
synthetically produced commercially by Twist Bioscience. A humanized V_{H}H framework characterized in Moutel et al.\textsuperscript{15} was used to house the designer CDRs.

Library was assembled as follows. The linear library DNA fragment was amplified by PCR. PCR reaction was divided into a 384-well format to minimize potential amplification bias. Five cycles of PCR were performed (Step 1: 98°C, 3 minutes, 1 cycle; Step 2: 98°C, 10 seconds; 68°C, 10 seconds; 72°C, 15 seconds, 5 cycles; Step 3: 72°C, 10 minutes, 1 cycle; Step 4: 12°C, hold). Amplified DNA was pooled and purified by Monarch Nucleic Acid Purification Kit (NEB, T1020S). The library was digested with 5 U/μg DNA SfiI at 50°C for 16 hours. Digest reactions were again column purified as previously mentioned. Ligation were set up as follows. pADL20c (205 μg) previously digested with BglII and treated with T4 S1 endonuclease was added to a 40 μL reaction containing the linear digested library (42 μg) at a vector to insert ratio of 1:2, 1 mM ATP and 1,000,000 units of T4 Ligase (Antibody Design Laboratories, PD0109). The reaction was allowed to proceed at 16°C for 16 hours, then at 37°C for 1 hour, and lastly was heat inactivated at 70°C for 20 minutes. DNA was purified and concentrated by a modified ethanol precipitation protocol utilizing tRNA carrier at 15 μg/mL.

Transformation of the library into TG1 E. coli was performed as follows. A total of 9 liters of fresh electrocompetent TG1 E. coli cells were produced and 150 electroporations performed. To 350 μL cells, 15 μL of ligated DNA was added and electroporation performed. After 1-hour recovery with the addition of 650 μL SOC at 37°C, cells were plated on 2xYT agar plates supplemented with 100 mM glucose and 100 μg/mL carbenicillin (2xYT-GA). E. coli was harvested after growth at 37°C for 16 hours, supplemented with glycerol to 10%, and stored at −80°C in aliquots for further use. Diversity of the nanobody library was determined by both NGS and colony PCR.

The V_{H}H library was added to 2xYT-GA to a final OD_{600} of 0.08 and allowed to grow at 37°C until an OD_{600} of 0.5 was reached. Superinfection with CM13 (Antibody Design Laboratories, PH020L) was performed with 2.0 × 10^{12} helper phage per liter of E. coli culture for 15 minutes without shaking followed by rigorous shaking for 30 minutes. Cells were collected by centrifugation at 5,500 × g for 10 minutes and resuspended in the previous volume used of 2xYT supplemented with 100 μg/mL carbenicillin and 50 μg/mL kanamycin (2xYT-AK). E. coli were grown overnight with shaking at 28°C.

Supernatant containing packaged phagemid was clarified by centrifugation at 6,000 × g for 15 minutes and supplemented with one-fourth volume 20% PEG-8000 and 2.5 M NaCl. Phage were precipitated overnight at 4°C and were collected by centrifugation at 5,500 × g for 60 minutes at 4°C. The pellet containing phage was resuspended in PBS and centrifuged for 15 minutes at 5,500 × g to remove E. coli particulates. Clarified phage was again precipitated as mentioned above and incubated on ice for 60 minutes. The phage was finally centrifuged at 17,900 × g for 10 minutes at 4°C, the supernatant was removed, and the pellet was again centrifuged at 17,900 × g for 1 minute to remove trace amounts of PEG-8000. The pellet was resuspended in PBS and passed through a 0.22 μm filter before determining the colony forming units (CFU).

**Next-generation sequencing**

All samples for NGS were processed as follows. The minimum region containing all 3 CDR domains, approximately 300 bps, was excised from the pADL20c backbone by two-step restriction digests, BglII followed by Ddel/BstEI double digests on the gel-purified small fragment from the BglII restriction reaction. The sequencing library was prepared using NEBNext\textsuperscript{TM} Ultra II Dual Library Prep Kit for Illumina\textsuperscript{®}(NEB, E7645S) and xGen\textsuperscript{™} UDI-UMI Adapters (IDT, 10,006,914) as instructed in the manufacture’s manuals and sequenced on Illumina NextSeq 500/550 platform with High Output v2.5 300-cycles (Illumina, 20,024,908), paired-end mode. BCL files were converted to FASTQ and demultiplexed using the bc1fastq script from Myllumina (https://my.illumina.com). The quality filtering and adaptor trimming were performed using fastp (https://github.com/OpenGene/fastp) with following parameters, -q 30 -l 100 -x 7. R2 read was reformatted to be reverse complemented and merged with R1 read using BBTools (BBMap, https://sourceforge.net/projects/bbmap/).\textsuperscript{27} Three CDR domains with correct sequence lengths were extracted, concatenated and translated and counted unique amino acid sequences using a custom python script.

**Affinity selection for SARS-CoV-2 S clones by panning**

A total of four rounds of affinity selection were conducted, three rounds against soluble full-length SARS-CoV-2 S and a final round against SARS-CoV-2 RBD. Panning was performed by immobilizing antigen in 96-well Immulon\textsuperscript{®} HBX microplates (Thermo, 3855). For the first round of panning, 3 μg SARS-CoV-2 S was immobilized in 50 μL coating buffer (100 mM NaHCO\textsubscript{3} (pH 8.3), 150 mM NaCl) overnight at 4°C. Wells containing antigen were washed five times with 300 μL PBS-t (phosphate buffered saline supplemented with 0.05% Tween-20). Wells were blocked with 300 μL Pierce PBS Protein Free Blocking Solution (Thermo, 37,572) for 2 hours. After another round of washing, 200 μL of 2.5 × 10^{12} CFU/mL phage were added to each well in blocking buffer and allowed to incubate with vigorous shaking at 25°C for 2 hours. Wells were extensively washed with increasing amounts of Tween-20, with a peak concentration of 0.5% Tween-20. Phage were eluted with the addition of 50 μL of elution buffer (100 mM Tris pH 7.4, 137 mM NaCl, 1 mM CaCl\textsubscript{2} and 100 μg/mL Trypsin) by incubating for 30 minutes at 37°C. Eluate was removed and pooled and a second 50 μL of elution buffer was added for 20 minutes. This was collected and pooled with the first round of elution buffer. Eluted phage was added to an equal volume of log phase TG1 E. coli for reamplification and quantification.

For all subsequent rounds of panning, 2 μg of antigen was used to coat wells. For round 2, a total of 10^{12} CFU phage were used for panning. For rounds 3 and 4, panning was conducted with an input of 10^{11} CFU phage. With each round of panning, washing was progressively increased from 12 washes in the first round to 15, then to 21 for the final two rounds. For all rounds after the first, a maximum of 1% Tween-20 was used for washing. The plates were then extensively washed with PBS to remove excess Tween-20. Additionally, the blocking solution for each round of panning was cycled. For the second
round, PBS-t supplemented with 1% bovine serum albumin (BSA) (w/v) was used, for the third round PBS-t supplemented with 2% nonfat milk, and for the final round BSA was again used. A denaturing step was conducted before the last round of panning against the SARS-CoV-2 RBD to remove unstable clones by heating the phage to 70°C for 15 minutes before panning. All other elution, reamplification, and tittering steps were conducted as mentioned above.

**Polyclonal and monoclonal phage ELISA**

Polyclonal phage ELISA was used to characterize antigenic enrichment and specificity for each round of panning. Multiple antigens were tested, including BSA, SARS-CoV-1 S, SARS-CoV-2 S, and SARS-CoV-2 RBD. Immulon HBX microtiter plates were blocked with 0.05 μg/well of each antigen overnight at 4°C. Plates were washed 5 times with PBS-t and blocked with 50 μL of PBS with 2% nonfat milk and 0.2% Tween-20 (MPBS-t). Plates were washed and 10° phage from the unenriched library and each round of panning was added to each well for all of the antigens in blocking solution. After 2 hours of shaking at 25°C, the plates were again washed 5 times and mouse anti-M13 coat protein (Thermo, MA299950) was added 1:2000 in MPBS-t for 1 hour. The plates were again washed, and rabbit antimouse IgG horseradish peroxidase (HRP; Thermo, PA1-28,568) was added 1:1000 in MPBS-t for 1 hour with shaking. The plates were finally washed 5 times with PBS-t and developed with TMB Ultra substrate (Thermo, 34,028) and quenched with 2 M H₂SO₄ (Sigma, 258,105) before reading the absorbance at 450 nm. Monoclonal phage ELISAs were performed in a similar fashion to the polyclonal ELISA mentioned above with homogeneous preparations of V₁H H-phage to validate individual clones.

**V₁H-huFc ELISA**

Indirect ELISAs were performed as follows. Full-length soluble SARS-CoV-2 S or RBD were immobilized on Immulon 384-well microtiter plates (0.05 μg/well) overnight at 4°C in coating buffer. After washing, plates were blocked for 2 hours with Pierce PBS Protein Free Blocking buffer. Serial dilutions of V₁H H-huFc antibodies in blocking buffer were added to plates for 2 hours after washing. Secondary antibody, goat anti-human H + L IgG HRP (Thermo, 31,410) was added for an additional hour before washing. Plates were developed with TMB Ultra and the reaction stopped by addition of equal volume 2 M H₂SO₄ after washing. Absorbance was read at 450 nm.

Competition of soluble ACE2-huFc by V₁H-huFc candidates identified from display screening was performed as follows. SARS-CoV-2 antigen was immobilized and blocked as described above. After blocking, serial dilutions of V₁H-huFc antibodies were prepared in blocking solution and allowed to incubate for at least 2 hours, after which ACE2-rbFc was added to a final concentration of 0.1 μg/mL (SARS-CoV-1 S) or 0.06 μg/mL (SARS-CoV-2 S) and allowed to incubate for 1 hour with shaking at 25°C. Plates were washed and 1:10,000 HRP-conjugated goat anti-rabbit IgG (Thermo, 31,466) was added. Plates were developed as described above.

**Differential scanning fluorimetry**

Thermostability for the V₁H-huFc antibodies was determined by DSF. Each reaction contained 10 μg of V₁H-huFc in PBS with 10 μM SYPRO Orange (Thermo, S6651). Reactions were heated from 10–95°C at a heating rate of 1°C/min and monitored in the FRET channel of a BioRad CFX96. The melting point for each of the V₁H-huFc antibodies was calculated by the first derivative method.

**Viruses and cell culture**

Vero and Vero E6 cells (African green monkey kidney, ATCC CCL-81 and CRL-1586, respectively) were maintained in culture medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, 15,070,063), at 37°C in 5% CO2. For risk group (RG) 2 experiments and viral stocks, Vero cells were cultured in supplemented minimum essential medium alpha (alpha MEM). For RG 3 experiments and viral stocks, Vero E6 cells were cultured in supplemented DMEM. A pseudotyped, replication-competent vesicular stomatitis virus (VSV) expressing eGFP as a marker of infection and the SARS-CoV-2 spike gene (VSV-SARS-CoV-2) in place of its own VSV-G gene was provided by Dr. Sean Whelan. Pseudotyped, single cycle VSV particles displaying the SARS-1 spike protein (VSV-SARS-1-GFP) were derived from recombinant VSV-DG-GFP in which the VSV-G envelope protein has been replaced with GFP. VSV-SARS-1-GFP single cycle particles were produced in Expi293 cells through transfection per manufacturer’s instructions with the SARS-CoV-1 spike expression plasmid (Sino Biological, VG40150-G-N) containing a 19-aa deletion in the cytoplasmic tail. The Expi293 cells were subsequently infected with VSV-DG-GFP, itself pseudotyped with VSV-G, at 72 h post-transfection using a multiplicity of infection (MOI) of 3. The resulting VSV-SARS-1-GFP pseudotyped viruses were collected at 24 h post-infection. WT SARS-CoV-2 was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52,281. An infectious clone of SARS-CoV-2 expressing a NeonGreen reporter gene (icSARS-CoV-2-mNG, or SARS-CoV-2-NG) was provided by Dr. Pei Yong Shi. Viral stocks were amplified in Vero E6 cells, supernatants were harvested upon extensive cytopathic effect, 48 (VSV-SARS-CoV -2-GFP) or 72 (SARS-CoV-2) hpi. Cellular debris was removed by centrifugation, and aliquots were stored at −80°C. Titers of viral stocks were determined by plaque assay. All work with WT SARS-CoV-2 was performed in Institutional Biosafety Committee approved BSL-3 and ABSL-3 facilities at Lawrence Livermore National Laboratory using appropriate personal protective equipment and protective measures.

**SARS-CoV-2 fluorescent reporter neutralization assays**

Serial dilutions of V₁H-huFc were prepared in supplemented media at 2× the desired final concentration. SARS-CoV-2-NG,
VSV-SARS-CoV-2-GFP, or VSV-SARS-1-GFP, was added to the serially diluted V1H-huFc antibodies for a final MOI of 0.2 (RG 2) or 0.1 (RG 3) and allowed to incubate at 37°C for 30 minutes to 1 hour with shaking prior to transfer of virus-V1H-huFc mixture to cells seeded in 96- (RG 3) or 384-well plates (RG 2). V1H-huFc-virus complexes were incubated with Vero cells at 37°C with 5% CO₂ for 12–16 h. For RG 2 experiments, cells were subsequently fixed in 4% paraformaldehyde (Millipore Sigma, 818,715) containing 10 mg/mL Hoechst 33,342 nuclear stain (Invitrogen, 62,249) for 30 min at room temperature, when fixative was replaced with PBS, and images were acquired with the Tecan Spark* Cyto multi-mode plate reader and image cytometer in both the DAPI and FITC channels to visualize nuclei and infected cells (i.e., eGFP-positive cells), respectively (4X objective, covering the entire well). Images were analyzed using the Spark Control Image Analyzer Software. For RG 3 experiments with, cells were lysed in RIPA buffer plus Halt protease inhibitor cocktail (Thermo, 87,786) and fluorescence was measured using 485 nm excitation and 528 emission wavelengths. Fluorescent values were calculated using no-infection controls and normalized to no-treatment infection values. The dose response curves and 50% effective inhibitory concentrations (EC₅₀) were generated using Graphpad Prism 9.

**Plaque neutralization assay**

V1H-huFc-W7 SARS-CoV-2 virus complexes were preincubated at 37°C with 5% CO₂ for 1 hour prior to addition to subconfluent Vero E6 cells in 12-well plates. After a 30-minute incubation of V1H-huFc-virus complexes with Vero E6 cells at 37°C with 5% CO₂, overlays of 2 mL per well of 0.6% microcrystalline cellulose (MCC, Sigma, 435,244), in 8% FBS, 1% P/S complemented 2X MEM were added. To stain, the MCC was aspirated, wells rinsed with PBS, and 0.4% crystal violet in 100% methanol was added for 10 minutes and then removed. Wells were then washed twice with water, and titers were recorded in PFU/mL.

**Biolayer interferometry**

Affinity measurements for V1H-huFc antibodies were performed using BLI using an Octet 384 Red system (Sartorius). Measurements were conducted in 10 mM phosphate (pH 7.4), 300 mM NaCl, 1 mg/mL BSA, 0.1% NP-40 (Thermo, 28,324). V1H-huFc ligands were immobilized on human Fc capturing sensors. W7 and mutant SARS-CoV-2 RBD were used as the analyte and sensorgrams were fit to a global 1:1 fit. Sensorgrams that deviated from a 1:1 global fit or fit well to a heterogeneous ligand model were designated as biphasic.

**Generation and analysis of escape mutants**

Mutant VSV-SARS-CoV-2-GFP virus with the ability to escape V1H-huFc neutralization was generated in a similar fashion to that described in Baum et al. In brief, a series of 500 μL dilutions of V1H-huFc antibodies were incubated with 500 μL of 1.5 × 10⁶ PFU VSV-SARS-CoV-2-GFP virus for 1 hour at 37°C. The V1H-huFc and virus mixture was added to Vero cells and allowed to incubate for up to 72 hours until apparent cytopathic effect (CPE) or widespread viral replication could be observed by GFP fluorescence. Supernatant from wells containing the highest concentrations of V1H-huFc was collected and viral RNA isolated from total RNA using TRIzol. A portion of this supernatant was diluted 500-fold and exposed to a series of higher concentrations of V1H-huFc antibodies for 1 hour at 37°C prior to addition to Vero cells. Cells were monitored for 60 hours for CPE and GFP fluorescence. Supernatants at the highest concentration of V1H-huFc with clear viral replication were collected and processed as mentioned above and viral RNA analyzed as described below.

**Statistical analysis**

Raw data for infection assays measured by reporter fluorescence were compared using a two-tailed t test for each individual experiment. For plate assays, untreated, infected controls and uninfected controls were included on every plate. Antibody-treated cells that were infected were compared to control samples infected with the same virus. Kaplan–Meier survival curves were generated based on two independent experiments and log rank tests were performed with Bonferroni multiple comparison correction applied (GraphPad Prism). P values were considered below.
significant when they were <0.05 (*) and very significant when they were <0.01 (**), <0.001 (***) or <0.0001 (****).

Acknowledgments

We would like to thank Prof. Sean Whelan from Washington University School of Medicine St. Louis for graciously providing access to the pseudotyped replication competent VSV-SARS-CoV-2-GFP virus used in this study. We would also like to thank Dr. Pei Yong Shi from the World Reference Center for Emerging Viruses and Arboviruses at University of Texas, Medical Branch for generously providing the infectious clone of SARS-CoV-2 expressing a NeonGreen reporter gene. We would also like to thank Robert Meager for critically reviewing the paper. This paper describes objective technical results and analysis. Any subjective views or opinions that might be expressed in the paper do not necessarily represent the views of the U.S. Department of Energy or the United States Government. All work performed at Lawrence Livermore National Laboratory is performed under the auspices of the U.S. Department of Energy under Contract DE-AC52-07NA27344.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| COVID-19 | Coronavirus disease 2019 |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| Vh | Nanobody |
| Fc | Crystallizable fragment |
| Vh-huFc | Nanobody-based humanized heavy chain only antibodies |
| RBD | Receptor-binding domain |
| ACE2 | Angiotensin-converting enzyme 2 |
| sdAbs | Single-domain heavy chain antibodies |
| IgG | Immunoglobulin G |
| CDR | Complementary determining region |
| BLI | Biolayer interferometry |
| BSA | Bovine serum albumin |
| PBS | Fetal bovine serum |
| DFS | Differential scanning fluorimetry |
| VSV | Vesicular stomatitis virus |
| RG2 | Risk Group 2 |
| RG3 | Risk Group 3 |
| CPE | Cytopathic effect |
| NGS | Next-generation sequencing |
| dpi | Days post-infection |
| hpi | Hours post-infection |

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 May;20(5):333–34. doi:10.1016/S1473-3099(20)30120-1.
2. Yimer B, Ashebir W, Wolde A, Teshome M. COVID-19 and Global Health Security: overview of the Global Health Security Alliance, COVID-19 response, African countries’ approaches, and ethics. Disaster Med Public Health Prep. 2020 Oct;21:5–. doi:10.1017/dmp.2020.360.
3. Katz LM. A little clarity on convalescent plasma for Covid-19. N Engl J Med. 2021 Feb 18;384(7):666–68. doi:10.1056/NEJMoa2035678.
4. Ali MG, Zhang Z, Gao Q, Pan M, Rowan EG, Zhang J. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. Immunol Res. 2020 Dec;68(6):325–39. doi:10.1007/s10539-020-09159-z.
5. Jiang S, Zhang X, Yang Y, Hotetz PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 Dec;4(12):1134–39. doi:10.1038/s41551-020-00660-2.
6. Byman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576–88. doi:10.1002/psp.12224.
7. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nikolola JP, Schafer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 2020 Aug 1;5847821:443–49. doi:10.1038/s41586-020-2548-6.
8. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofal D, Im J et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238–51. doi:10.1056/NEJMoa2035002.
9. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Morechler B, Stosor V et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):229–37. doi:10.1056/NEJMoa2029849.
10. Mitchell LS, Colwell LJ. Comparative analysis of nanobody sequence and structure data. Proteins. 2018 Jul;86(7):697–706. doi:10.1002/prot.25497.
11. Harnsen MM, De Haard HJ. Properties, production, and applications of cam Facilities single-domain antibody fragments. Appl Microbiol Biotechnol. 2007 Nov;77(1):13–22. doi:10.1007/s00253-007-1142-2.
12. Bannas P, Hambach J. Nanobodies K-NF. Nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603–1603. doi:10.3389/fimmu.2017.01603.
13. Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020 Sep 14;10(1):14991. doi:10.1038/s41598-020-71748-7.
14. Wilton EE, Oppy MP, Kailasam S, Kothe RE, Wieden H-J, sdAB-DB: the Single Domain Antibody Database. ACS Synth Biol. 2018 Nov 16;7(11):2480–84. doi:10.1021/acssynbio.8b00407.
15. Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, Ligat L, Rain JC, Favre G, Olichon A, et al. NaI-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;15:e16228.
16. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Driolt L, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host & Microbe. 2020 2020 Nov 20;29(3):475–485.e5.
17. Dong J, Huang B, Wang B, Titong A, Gallolu Kankanamalage S, Jia Z, Wright M, Parthasarathy P, Liu Y. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. Sci Rep. 2020 Oct 20;10(1):17806. doi:10.1038/s41598-020-74761-y.
18. Winkler ES, Bailey AL, Kafai NM, Nair S, McCune BT, Yu J, Fox JM, Chen RE, Earnest JT, Keeler SP, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020 Nov;21(11):1327–35. doi:10.1038/s41590-020-07778-2.
19. What is the economic cost of covid-19? The Economist. 2021 Jan 7, 2021.

Funding

This work was supported by the Laboratory Directed Research and Development Program at Sandia National Laboratories and the Department of Energy (DOE) Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. Sandia National Laboratories is a multi-mission managed and operated by National Technology & Engineering Solutions of Sandia, LLC, a wholly owned subsidiary of Honeywell International Inc., for the U.S. Department of Energy’s National Nuclear Security Administration under contract DE-NA0003525;

ORCID

Brooke Harmon http://orcid.org/0000-0003-0621-5320
20. FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization [Internet]. U.S. Food & Drug Administration; 2021; Mar 10, 2021.[1]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-antibody-products-under

21. Baum A, Fulton BO, Wlode E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020 Aug 21;369(6506):1014–18. doi:10.1126/science.abb0831.

22. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009 Jun 30; received Sep 1; revised 01/12; accepted:1572:220–33. doi:10.1039/b70831e.2009.190.x.

23. Dhama K, Sharun K, Tiwari R, Darad M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Jun 2;16(6):1232–38. doi:10.1177/2164551520735227.

24. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Nov 20;584(7819):115-119.

25. Schoof M, Faust B, Saunders RA, Sangwan S, Rezeli V, Hoppe N, Boone M, Billesbolle CB, Puchades C, Azumaya CM, et al. An ultrasensitive synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020 Dec 18;370(6523):1473–79.

26. Li W, Schäfer A, Kulkarni SS, Liu X, Martinez DR, Chen C, Sun Z, Leit SR, Drelich A, Zhang L, et al. High potency of a bivalent human V(H) domain in SARS-CoV-2 animal models. Cell. 2020 Oct 15;183(2):429–41. e16. doi:10.1016/j.cell.2020.09.007.

27. Wesolowski J, Alzogary V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Risssie B, Scheuplein F, et al. Single domain antibodies: promising experimental and therapeutical tools in infection and immunity. Med Microbiol Immunol. 2009 Aug;198(3):157–74. doi:10.1007/s00430-009-0116-7.

28. Huo J, Le Bas A, Raza RK, Duyvesteyn HME, Mikolajek H, Malinauskas T, Tan TK, Rijal P, Dumoux M, Ward PN, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020 Sep 1;27(9):846–54. doi:10.1038/s41594-020-0469-6.

29. Koenig P-A, Das H, Liu H, Kümmner BM, Goehr FN, Jenster L-M, Schifflers LDJ, Tesfamariam YM, Uchima M, Wuerth JD, et al. Structure-guided multivalent nanobodies block SARS-CoV-2 spike infection and suppress mutational escape. Science. 2021;371 (6530):eabe6230. doi:10.1126/science.abe6230.

30. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L, Hoffmann M, Pöhlmann S, et al. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell. 2020;181(5):1004–1015. e15. doi:10.1016/j.cell.2020.04.031.

31. Bracken CJ, Lim SA, Solomon P, Rettko NJ, Nguyen DP, Zha BS, Schaefer K, Byrnes JR, Zhou J, Liu I, et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 2021 Jan;17(1):113–21. doi:10.1038/s41550-020-00679-1.

32. Sun Z, Chen C, Li W, Martinez DR, Drelich A, Baek D-S, Liu X, Mellors JW, Tseng C-T, Baric RS et al. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MABS. 2020 Jan 1;12(1):1778435. doi:10.1016/j.19420862.2020.1778435.

33. Lu Q, Zhang Z, Li H, Zhong K, Zhao Q, Wang Z, Wu Z, Yang D, Sun S, Yang N, et al. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021 Jan 29;19133. doi:10.1186/s12951-021-00768-w.

34. Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex PW, Schneider-Duhovny D, Zhang C, Shi Y. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479–84.